Open AccessEvaluation of cardiopulmonary exercise test in the prediction of disease progression in systemic sclerosis
Author(s) -
Rita Hemelein,
Imre Lajkó,
Kristóf Baráth,
J. Várga,
Gergely Ágoston,
Daniella Hulló,
Márta Bocskai,
Diána Dobi,
Zoltán Rózsavölgyi,
Ágnes Milassin,
Albert Varga,
Attila Somfay,
László Kovács
Publication year - 2021
Publication title -
clinical and experimental rheumatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.184
H-Index - 95
eISSN - 1593-098X
pISSN - 0392-856X
DOI - 10.55563/clinexprheumatol/tktu8v
Subject(s) - medicine , cardiology , pulmonary function testing , anaerobic exercise , pulmonary hypertension , vo2 max , cohort , vital capacity , clinical endpoint , lung , physical therapy , blood pressure , heart rate , lung function , diffusing capacity , randomized controlled trial
Cardiopulmonary exercise test (CPET) is a widely used examination to predict the prognosis of many chronic pulmonary diseases, and it has also been tested in systemic sclerosis (SSc) with a focus on the development of pulmonary hypertension. CPET is a highly informative non-invasive tool that provides a more complex information than conventional lung function tests to predict the course of cardiopulmonary diseases, as it provides a general overview of the aerobic metabolism, influenced by pulmonary, cardiovascular and peripheral muscle function. The purpose of this investigation was to assess if the progression and the development of poor overall disease outcome in SSc can be predicted by this method.